Inhibition of glutathione synthesis eliminates the adaptive response of ascitic hepatoma 22 cells to nedaplatin that targets thioredoxin reductase

Toxicology and Applied Pharmacology

Volumn 265, Issue 3, 2012, Pages 342-350

  Wang, Yijun ^a   Lu, Hongjuan ^b   Wang, Dongxu ^a   Li, Shengrong ^a   Sun, Kang ^a   Wan, Xiaochun ^a   Taylor, Ethan Will ^c   Zhang, Jinsong ^a  

^a ANHUI AGRICULTURAL UNIVERSITY   (China)

^b Productivity Center of Jiangsu Province   (China)

^c UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

Buthionine sulfoximine Glutathione Nedaplatin Thioredoxin reductase; Buthionine sulfoximine; Glutathione; Nedaplatin; Thioredoxin reductase

Indexed keywords

BUTHIONINE SULFOXIMINE; GLUTATHIONE; NEDAPLATIN; THIOREDOXIN REDUCTASE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASCITES HEPATOMA; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GLUTATHIONE METABOLISM; HEPATOMA CELL; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PROTEIN TARGETING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; BUTHIONINE SULFOXIMINE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GLUTATHIONE; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; ORGANOPLATINUM COMPOUNDS; RANDOM ALLOCATION; THIOREDOXIN-DISULFIDE REDUCTASE;

MUS;

EID: 84870296650     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.09.001     Document Type: Article

References (55)

1. Alberto M.E., Lucas M.F., Pavelka M., Russo N. The second-generation anticancer drug nedaplatin: a theoretical investigation on the hydrolysis mechanism. J. Phys. Chem. B 2009, 113:14473-14479.
2. Alberts B., Johnson A., Lewis J., Raff M., Roberts K., Walter P. Molecular Biology of the Cell 2008, Garland Science, New York. 5th edition.
3. Andringa K.K., Coleman M.C., Aykin-Burns N., Hitchler M.J., Walsh S.A., Domann E.E., Spitz D.R. Inhibition of glutamate cysteine ligase activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-d-glucose. Cancer Res. 2006, 66:1605-1610.
4. Anestål K., Arnér E.S. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J. Biol. Chem. 2003, 278:15966-15972.
5. Anestål K., Prast-Nielsen S., Cenas N., Arnér E.S. Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells. PLoS One 2008, 3:e1846.
6. Arnér E.S. Focus on mammalian thioredoxin reductases - important selenoproteins with versatile functions. Biochim. Biophys. Acta 2009, 1790:495-526.
7. Barranco S.C., Townsend C.M., Weintraub B., Beasley E.G., MacLean K.K., Shaeffer J., Liu N.H., Schellenberg K. Changes in glutathione content and resistance to anticancer agents in human stomach cancer cells induced by treatments with melphalan in vitro. Cancer Res. 1990, 50:3614-3618.
8. Biroccio A., Benassi B., Fiorentino F., Zupi G. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 2004, 6:195-206.
9. Brigelius-Flohé R., Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim. Biophys. Acta 2009, 1790:1555-1568.
10. Cai W., Zhang L., Song Y., Wang B., Zhang B., Cui X., Hu G., Liu Y., Wu J., Fang J. Small molecule inhibitors of mammalian thioredoxin reductase. Free Radic. Biol. Med. 2012, 52:257-265.
11. Cai W., Zhang B., Duan D., Wu J., Fang J. Curcumin targeting the thioredoxin system to elevate oxidative stress in HeLa cells. Toxicol. Appl. Pharmacol. 2012, [Epub ahead of print].
12. Carlberg I., Mannervik B. Glutathione reductase. Methods Enzymol. 1985, 113:484-490.
13. Dai J., Weinberg R.S., Waxman S., Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999, 93:268-277.
14. Davis W., Ronai Z., Tew K.D. Cellular thiols and reactive oxygen species in drug-induced apoptosis. J. Pharmacol. Exp. Ther. 2001, 296:1-6.
15. Desoize B., Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit. Rev. Oncol. Hematol. 2002, 42:317-325.
16. Fath M., Ahmad I.M., Smith C.J., Spence J.M., Spitz D.R. Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin. Cancer Res. 2011, 17:6206-6217.
17. Gladyshev V.N., Jeang K.T., Stadtman T.C. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:6146-6151.
18. Gottesman M.M., Pastan I. Resistance to multiple chemotherapeutic agents in human cancer cells. Trends Pharmacol. Sci. 1988, 9:54-58.
19. Gromer S., Urig S., Becker K. The thioredoxin system - from science to clinic. Med. Res. Rev. 2004, 24:40-89.
20. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione S-transferases: the first enzymatic step in mercapturic acid formation. J. Biol. Chem. 1974, 249:7130-7139.
21. Hall A., Nelson K., Poole L.B., Karplus P.A. Structure-based insights into the catalytic power and conformational dexterity of peroxiredoxins. Antioxid. Redox Signal. 2011, 15:795-815.
22. Holmgren A. Thioredoxin and glutaredoxin systems. J. Biol. Chem. 1989, 264:13963-13966.
23. Holmgren A., Björnstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol. 1995, 252:199-208.
24. Hsu M.H., Liu C.Y., Lin C.M., Chen Y.J., Chen C.J., Lin Y.F., Huang L.J., Lee K.H., Kuo S.C. 2-(3-Methoxyphenyl)-5-methyl-1,8-naphthyridin-4(1H)-one (HKL-1) induces G2/M arrest and mitotic catastrophe in human leukemia HL-60 cells. Toxicol. Appl. Pharmacol. 2012, 259:219-226.
25. Hunter K.J., Deen D.F., Marton L.J. Changes in the glutathione content of rat 9L cells induced by treatment with the ornithine decarboxylase inhibitor alpha-difluoromethylornithine. Cancer Res. 1987, 47:5270-5273.
26. Kawai Y., Taniuchi S., Okahara S., Nakamura M., Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol. Pharm. Bull. 2005, 28:1385-1388.
27. Koshiyama M., Kinezaki M., Uchida T., Sumitomo M. Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin. Anticancer Res. 2005, 25:4499-4502.
28. Lee F.Y., Vessey A., Rofstad E., Siemann D.W., Sutherland R.M. Heterogeneity of glutathione content in human ovarian cancer. Cancer Res. 1989, 49:5244-5248.
29. Lu J., Chew E.H., Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12288-12293.
30. Meurette O., Lefeuvre-Orfila L., Rebillard A., Lagadic-Gossmann D., Dimanche-Boitrel M.T. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations. Clin. Cancer Res. 2005, 11:3075-3083.
31. Monk B.J., Alberts D.S., Burger R.A., Fanta P.T., Hallum A.V., Hatch K.D., Salmon S.E. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers. Gynecol. Oncol. 1998, 71:308-312.
32. Nguyen P., Awwad R.T., Smart D.D., Spitz D.R., Gius D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. 2006, 236:164-174.
33. Nordberg J., Arnér E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 2001, 31:1287-1312.
34. Ogawa M. 254-S, NK121 and TRK710 1996, 193-197. Plenum Press, New York. H.M. Pinedo, J.H. Schornagel (Eds.).
35. Pennington J.D., Jacobs K.M., Sun L., Bar-Sela G., Mishra M., Gius D. Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr. Pharm. Des. 2007, 13:3368-3377.
36. Rotruck J.T., Pope A.L., Ganther H.E., Swanson A.B., Hafeman D.G., Hoekstra W.G. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973, 179:588-590.
37. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998, 17:2596-2606.
38. Sasaki Y., Amano T., Morita M., Shinkai T., Eguchi K., Tamura T., Ohe Y., Kojima A., Saijo N. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res. 1991, 51:1472-1477.
39. Satoh M., Shimada A., Zhang B., Tohyama C. Renal toxicity caused by cisplatinum in glutathione-depleted metallothionein-null mice. Biochem. Pharmacol. 2000, 60:1729-1734.
40. Scarbrough P.M., Mapuskar K.A., Mattson D.M., Gius D., Watson W.H., Spitz D.R. Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. Free Radic. Biol. Med. 2012, 52:436-443.
41. Steinbrenner H., Sies H. Protection against reactive oxygen species by selenoproteins. Biochim. Biophys. Acta 2009, 1790:1478-1485.
42. Stordal B., Davey M. Understanding cisplatin resistance using cellular models. IUBMB Life 2007, 59:696-699.
43. Sun Y., Oberley L.W., Li Y. A simple method for clinical assay of superoxide dismutase. Clin. Chem. 1988, 34:497-500.
44. Thamsen M., Kumsta C., Li F., Jakob U. Is overoxidation of peroxiredoxin physiologically significant?. Antioxid. Redox Signal. 2011, 14:725-730.
45. Tonissen K.F., Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol. Nutr. Food Res. 2009, 53:87-103.
46. Troyano A., Fernández C., Sancho P., de Blas E., Aller P. Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation. J. Biol. Chem. 2001, 276:47107-47115.
47. Vermorken J.B. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer. Int. J. Gynecol. Cancer 2001, 11(Suppl.):121-130.
48. Wang X., Zhang J., Xu T. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. Toxicol. Appl. Pharmacol. 2007, 218:88-95.
49. Wang X., Zhang J., Xu T. Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy. Eur. J. Pharmacol. 2008, 579:66-73.
50. Witte A.B., Anestål K., Jerremalm E., Ehrsson H., Arnér E.S. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic. Biol. Med. 2005, 39:696-703.
51. Wu X.X., Ogawa O., Kakehi Y. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by l-buthionine sulfoximine. Int. J. Oncol. 2004, 24:1489-1497.
52. Yoo M.H., Xu X.M., Carlson B.A., Gladyshev V.N., Hatfield D.L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem. 2006, 281:13005-13008.
53. Zhang J., Lu H. Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity. Free Radic. Biol. Med. 2007, 43:1574-1583.
54. Zhang J., Wang X., Lu H. Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase. Cancer Lett. 2008, 260:127-136.
55. Zhu A.X. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?. Oncologist 2006, 11:790-800.